Abstract
Background COVID-19 led to a disruption in nearly all aspects of society, yet these impacts were not the same across populations. During the pandemic, it became apparent that ancestry was associated with COVID-19 severity and morbidity, such that individuals of African descent tended to have worse outcomes than other populations. One factor that may influence COVID-19 outcomes is the circulating proteomic response to infection. This study examines how different ancestries had differential circulating protein levels in response to severe COVID-19 infection.
Methods 4,979 circulating proteins from 1,272 samples were measured using the SomaScan platform. We used a linear mixed model to assess the ancestry-specific association between the level of each protein and severe COVID-19 illness, accounting for sex, age, and days since symptom onset. We then compared each ancestry-specific effect size of severe COVID-19 illness on protein level to one another in a pairwise manner to generate Z-scores. These Z-scores were then converted into p-values and corrected for multiple comparisons using a Benjamini-Hochberg false discovery rate of 5%.
Results Comparing ancestries, we found that 62% of the tested proteins are associated with severe COVID-19 in European-ancestry individuals, compared to controls. We found that 45% and 22% of the tested proteins were different between COVID-19 infected and control individuals in people of African and East Asian ancestry, respectively. There was a strong correlation in effect size between ancestries. We found that individuals of European and African ancestry had the most similar response with a Pearson correlation of 0.868, 95% CI [0.861, 0.875] while European and East Asian ancestries had a Pearson correlation of 0.645, 95% CI [0.628, 0.661] and, East Asian and African ancestries had a Pearson correlation of 0.709, 95% CI [0.695, 0.722]. However, we found 39 unique proteins that responded differently (FDR < 0.05) between the three ancestries.
Conclusions Examining 4,979 protein levels in 1,272 samples, we identified that the majority of measured proteins had similar responses to infection across individuals of European, African and East Asian ancestry. However, there were 39 proteins that may have a differential response to infection, when stratified by ancestry. These proteins could be investigated to assess whether they explain the differences in observed severity of COVID-19 between ancestral populations.
Competing Interest Statement
JBRs institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and Biogen for projects unrelated to this research. JBR is the CEO of 5 Prime Sciences (www.5primesciences.com), which provides research services for biotech, pharma and venture capital companies for projects unrelated to this research. T.N. has received a speaking fee from Boehringer Ingelheim for the talks unrelated to this research. L.C. is a full-time employee of SomaLogic Inc.
Funding Statement
The Richards research group is supported by the Canadian Institutes of Health Research (CIHR: 365825; 409511, 100558, 169303), the McGill Interdisciplinary Initiative in Infection and Immunity (MI4), the Lady Davis Institute of the Jewish General Hospital, the Jewish General Hospital Foundation, the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK, Genome Québec, the Public Health Agency of Canada, McGill University, Cancer Research UK [grant umber C18281/A29019] and the Fonds de Recherche Québec Santé (FRQS). JBR is supported by a FRQS Mérite Clinical Research Scholarship. Support from Calcul Québec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guys and St Thomas NHS Foundation Trust in partnership with Kings College London. T.N. is supported by a research fellowship of the Japan Society for the Promotion of Science for Young Scientists (22J30004). These funding agencies had no role in the design, implementation or interpretation of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent for inclusion in this study was obtained from every patient or their legal representatives. The IRB of the Jewish General Hospital and the Centre Hospitalier de l'Université de Montréal gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author List and Affiliations Updated; Spelling Errors; Legend on Figure 1 updated to clarify FDR.
Data Availability
The BQC19 is an Open Science Biobank. Instructions on how to access data for individuals from the BQC19 is available at https://www.bqc19.ca/en/access-data-samples. To see the code used to analyze this data, it is available at https://github.com/richardslab/BQC_Ancestry_Proteomics.
List of abbreviations
- COVID-19
- Coronavirus disease 19
- BQC19
- Biobanque Quebecois de la COVID-19
- LMM
- Linear mixed model
